Busby, JohnKarasneh, ReemaMurchie, PeterMcMenamin, ÚnaGadalla, Shahinaz M.Camargo, M. ConstanzaIversen, LisaLee, Amanda J.Spence, Andrew D.Cardwell, Chris R.2020-11-122020-11-122020-01Busby, J, Karasneh, R, Murchie, P, McMenamin, Ú, Gadalla, S M, Camargo, M C, Iversen, L, Lee, A J, Spence, A D & Cardwell, C R 2020, 'The role of 5α‐reductase inhibitors in gastro‐oesophageal cancer risk : A nested case‐control study', Pharmacoepidemiology and Drug Safety, vol. 29, no. 1, pp. 48-56. https://doi.org/10.1002/pds.49091053-8569ORCID: /0000-0001-9968-5991/work/83704212ORCID: /0000-0002-4865-9061/work/159078259https://hdl.handle.net/2164/153559358678engSDG 3 - Good Health and Well-beinggastric canceroesophageal cancerAndrogen5α-reductase inhibitorANDROGEN RECEPTORandrogenADENOCARCINOMAFINASTERIDEBARRETTS-ESOPHAGUS5 alpha-reductase inhibitorSEX-HORMONE RECEPTORSGASTRIC-CANCERCELL-MIGRATIONPROSTATE-CANCERESOPHAGEAL CANCEREXPRESSIONRC0254 Neoplasms. Tumors. Oncology (including Cancer)Pharmacology (medical)EpidemiologySupplementary DataRC0254Journal article10.1002/pds.4909http://www.scopus.com/inward/record.url?scp=85075021588&partnerID=8YFLogxK291